AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

Imfinzi for stage III NSCLC that cannot be removed by surgery (PACIFIC study). On average, people who were treated with Imfinzi lived 16.8 months before their cancer got worse.

IMFINZI with IMJUDO and Platinum-Based Chemotherapy. Infusion-related reactions occurred in 2.9% (17/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, ...

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...

Imfinzi and Keytruda are both prescription drugs that treat certain types of cancer. Learn how their uses, effectiveness, and side effects compare.

Imfinzi and Tecentriq are both drugs used to treat certain cancers. Learn how they’re similar and different to help you decide if one may be right for you.